Zevra Therapeutics, Inc. (ZVRA)

Nasdaq: ZVRA · Pharmaceutical Preparations · Boston, MA · filing with the SEC since 2008

Full chart Alerts Compare

Grade5.6

◀ Past 4.5● Present 5.8▶ Future 6.1

1 est.

Overview Business Financials Grade Forecast Sentiment Ownership People Filings Patents Chart

The grade of Zevra Therapeutics, Inc.

Nine metrics read from its own filings, by tense

Headline grade

5.6/10

◀ Past4.525% of the headline

● Present5.835% of the headline

▶ Future6.140% of the headline

All three tenses have at least two readings, so the archetype blend applies as printed.

Of the nine metrics, 8 read as filed from the record and 1 is an SI estimate, each with its reasoning, its confidence and what would change it on its card.

◀ Past

What did they actually do?

4.5/1025% of the headline grade · 2 of 3 filed, 1 estimated

Surviving crises

as filed

0.7/10

Has it survived what it has been through?

12 warning events since 2017; the latest 2024-03-28.

weight 22% of this tense · 7th percentile among 497 sector filers · read for itself

From the record

Zevra Therapeutics, Inc.'s filings since 2017 show 12 warning events of 4 kinds: a notice about its exchange listing (8-K item 3.01, 8 times, the latest 2020-05-20); a warning not to rely on past financial statements (8-K item 4.02, the latest 2024-03-28); an auditor change (8-K item 4.01, 2 times, the latest 2022-06-17); a late-report notice (Form NT 10-K or NT 10-Q, the latest 2017-05-16) (its current reports).

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Track record

as filed

5.7/10

What has it actually done, year after year?

8 filed years; profitable in 1 of 8.

weight 45% of this tense · 57th percentile among 323 sector filers · read for its customers

From the record

Zevra Therapeutics, Inc.'s 8 filed years say what it did: it rose in 4 of 6 years; the deepest fall was 65% from fiscal 2021 to fiscal 2022; net income was positive in 1 of 8 of those years (its annual reports).

What it rests on

the share of years revenue rosetop 41% of its family
the share of filed years with a profittop 35% of its family
the deepest fall from a revenue peak64.5%bottom 48% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Shareholder treatment

SI estimate

5.4/10

How has it treated the people who own it?

SI estimate 5.4/10, confidence 35 of 100 (one part).

weight 33% of this tense · 54th percentile among 464 sector filers · read for its shareholders

SI estimate Inferred, not read as filed

Why it is an estimate: Read from one part only, the share count over the years, which ranks in the top 46% of 464 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income.
What the record cannot read: Fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income.
How it was reasoned: one part: the share count over the years, the one part on file, ranked among 464 in its family.
Confidence: 35 of 100
What would change it: A filing that carries the missing parts replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: Zevra Therapeutics, Inc.'s shareholder treatment is put at 5.4 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the top 46% of 464 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.

● Present

What are they doing right now?

5.8/1035% of the headline grade · 3 of 3 filed

Financial health

as filed

6.2/10

Is it financially healthy right now?

ROE 54%: 54¢ of profit per shareholder dollar. Leverage 46%: owes 46¢ per asset dollar.

weight 45% of this tense · 62nd percentile among 473 sector filers · read for itself

From the record

Return on equity: in the fiscal year ended 2025-12-31, Zevra Therapeutics, Inc. earned about 54 cents of profit for every dollar of shareholders' money. Leverage: it owed about 46 cents per dollar of assets, and net share issuance: its share count grew 19.6% over the year (the filed statements).

What it rests on

what it owes per dollar of assetsbottom 38% of its family
return on equitytop 2% of its family
the share count against the year beforetop 50% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Industry position

as filed

8.4/10

How strong is its position in its industry?

top 16% of 315 in its family; net margin 78.2%.

weight 22% of this tense · 84th percentile among 315 sector filers · read for its customers

From the record

Zevra Therapeutics, Inc.'s standing among 315 graded names in its industry family: revenue of $106 million in fiscal 2025 ranks in the top 34% by size; a net margin of 78.2% ranks in the top 4%; revenue growth of 118.8% a year over the last 3 filed years ranks in the top 11% (its annual reports).

What it rests on

revenue against the family$106Mtop 34% of its family
net margin78.2%top 4% of its family
three-year revenue growth118.8%top 11% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Leadership

as filed

3.6/10

What are the people in charge doing?

bottom 36% of 315 in its family for leadership; chief executive since 2023.

weight 33% of this tense · 36th percentile among 315 sector filers · read for its shareholders

From the record

Zevra Therapeutics, Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Mcfarlane, Neil F. (President and CEO, as filed), filing under that title since 2023-10-10, 3.1 years (bottom 33% of its family); the 14 officers and directors filing in the last fifteen months have been on the record a median of 3.4 years (bottom 19%); 6 officer or director changes were reported on Form 8-K since 2023-11-13, against the 14 people in charge now (top 45%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

What it rests on

officer and director changes on Form 8-K, against the people in charge6 in three years among 14 peopletop 45% of its family
the median years the people in charge have filed3.4 yearsbottom 19% of its family
the chief executive's years on the record3.1 yearsbottom 33% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

▶ Future

What are they set up to do next?

6.1/1040% of the headline grade · 3 of 3 filed

Room to expand

as filed

3.4/10

How much room does it have to grow?

bottom 34% of 273 in its family for room to expand.

weight 33% of this tense · 34th percentile among 273 sector filers · read for itself

From the record

Zevra Therapeutics, Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $62 million against debt of $62 million leaves 0.2% of its assets as net cash, bottom 14% of its family; cash from operations less capital spending is -2.3% of revenue (top 31%); research spending of 12% of revenue (bottom 17%) (its annual report).

What it rests on

cash less debt against assets0.2%bottom 14% of its family
cash from operations less capital spending against revenue-2.3%top 31% of its family
research spending against revenue12.0%bottom 17% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Growth drivers

as filed

7.0/10

What could actually drive growth from here?

top 30% of 306 in its family for growth drivers.

weight 45% of this tense · 70th percentile among 306 sector filers · read for its customers

From the record

Zevra Therapeutics, Inc.'s growth drivers, from the filed years to fiscal 2025: the newest year grew 351.4% (top 8%); research spending grew -13.7% a year (bottom 25%); capital spending grew 107.8% a year (top 8%) (its annual reports). Zevra Therapeutics, Inc. tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.

What it rests on

the newest year's revenue growth351.4%top 8% of its family
three-year growth of research spending-13.7%bottom 25% of its family
three-year growth of capital spending107.8%top 8% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Expectations vs reality

as filed

8.7/10

Did its newest year beat what its own record pointed to?

top 13% of 233 in its family for expectations against reality.

weight 22% of this tense · 87th percentile among 233 sector filers · read for its shareholders

From the record

Zevra Therapeutics, Inc.'s newest year against its own record: revenue of $106 million in fiscal 2025 came in 195.9% above the $36 million its prior three years' pace pointed to (top 11% of its family); net income of $83 million against a prior three-year average of $59 million (top 6%); a net margin of 78.2% against losses larger than its revenue before (top 22%) (its annual reports).

What it rests on

revenue against the prior three years' pace195.9%top 11% of its family
net income against the prior three years' average+240%top 6% of its family
net margin against its prior averageup more than 100 pointstop 22% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made

SI Assistanton ZVRA · research, not advice